P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Nov 16

PMID 33194688

Citations 64

Authors

Anna Seelig

Affiliations

Soon will be listed here.

Abstract

P-glycoprotein or multidrug resistance protein (MDR1) is an adenosine triphosphate (ATP) binding cassette transporter (ABCB1) intensely investigated because it is an obstacle to successful pharmacotherapy of cancers. P-glycoprotein prevents cellular uptake of a large number of structurally and functionally diverse compounds, including most cancer therapeutics and in this way causes multidrug resistance (MDR). To overcome MDR, and thus improve cancer treatment, an understanding of P-glycoprotein inhibition at the molecular level is required. With this goal in mind, we propose rules that predict whether a compound is a modulator, substrate, inhibitor, or inducer of P-glycoprotein. This new set of rules is derived from a quantitative analysis of the drug binding and transport properties of P-glycoprotein. We further discuss the role of P-glycoprotein in immune surveillance and cell metabolism. Finally, the predictive power of the proposed rules is demonstrated with a set of FDA approved drugs which have been repurposed for cancer therapy.

Citing Articles

Potentiation of Doxorubicin Cytotoxicity Utilizing Clarithromycin Loaded-PEGylated Liposomes.

Alfreahat I, Nsairat H, Aldeeb I, Al-Samydai A, Alshaer W Technol Cancer Res Treat. 2025; 24:15330338241312561.

PMID: 39865928 PMC: 11770720. DOI: 10.1177/15330338241312561.

Ivermectin Strengthens Paclitaxel Effectiveness in High-Grade Serous Carcinoma in 3D Cell Cultures.

Nunes M, Ricardo S Pharmaceuticals (Basel). 2025; 18(1.

PMID: 39861076 PMC: 11769219. DOI: 10.3390/ph18010014.

Identification of promising SARS-CoV-2 main protease inhibitor through molecular docking, dynamics simulation, and ADMET analysis.

Sharma G, Kumar N, Sharma C, Alqahtani T, Tiruneh Y, Sultana S Sci Rep. 2025; 15(1):2830.

PMID: 39843610 PMC: 11754916. DOI: 10.1038/s41598-025-86016-9.

Overcoming Challenges in Small-Molecule Drug Bioavailability: A Review of Key Factors and Approaches.

Wu K, Kwon S, Zhou X, Fuller C, Wang X, Vadgama J Int J Mol Sci. 2024; 25(23.

PMID: 39684832 PMC: 11642056. DOI: 10.3390/ijms252313121.

Low-Dose Perifosine, a Phase II Phospholipid Akt Inhibitor, Selectively Sensitizes Drug-Resistant ABCB1-Overexpressing Cancer Cells.

Park J, Lee H, Zheng T, Shin J, Yoon S, Kim H Biomol Ther (Seoul). 2024; 33(1):170-181.

PMID: 39632683 PMC: 11704409. DOI: 10.4062/biomolther.2024.069.

References

Kim H, Hien T, Han E, Hwang Y, Choi J, Kang K . Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol. 2010; 162(5):1096-108. PMC: 3051382. DOI: 10.1111/j.1476-5381.2010.01101.x. View

Cordon-Cardo C, OBrien J, CASALS D, Biedler J, Melamed M, Bertino J . Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989; 86(2):695-8. PMC: 286540. DOI: 10.1073/pnas.86.2.695. View

Park M, Hong J . Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches. Cells. 2016; 5(2). PMC: 4931664. DOI: 10.3390/cells5020015. View

Cordon-Cardo C, OBrien J, Boccia J, CASALS D, Bertino J, Melamed M . Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990; 38(9):1277-87. DOI: 10.1177/38.9.1974900. View

Li D, Chen L, Li Y, Tian S, Sun H, Hou T . ADMET evaluation in drug discovery. 13. Development of in silico prediction models for P-glycoprotein substrates. Mol Pharm. 2014; 11(3):716-26. DOI: 10.1021/mp400450m. View

Chufan E, Kapoor K, Ambudkar S . Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein. Biochem Pharmacol. 2015; 101:40-53. PMC: 4753104. DOI: 10.1016/j.bcp.2015.12.007. View

van de Ven R, Oerlemans R, van der Heijden J, Scheffer G, de Gruijl T, Jansen G . ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. J Leukoc Biol. 2009; 86(5):1075-87. DOI: 10.1189/jlb.0309147. View

Zibell G, Unkruer B, Pekcec A, Hartz A, Bauer B, Miller D . Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology. 2009; 56(5):849-55. DOI: 10.1016/j.neuropharm.2009.01.009. View

Omote H, Al-Shawi M . Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys J. 2006; 90(11):4046-59. PMC: 1459527. DOI: 10.1529/biophysj.105.077743. View

10.

McClean S, Hosking L, Hill B . Dominant expression of multiple drug resistance after in vitro X-irradiation exposure in intraspecific Chinese hamster ovary hybrid cells. J Natl Cancer Inst. 1993; 85(1):48-53. DOI: 10.1093/jnci/85.1.48. View

11.

Egido E, Muller R, Li-Blatter X, Merino G, Seelig A . Predicting Activators and Inhibitors of the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1) Based on Mechanistic Considerations. Mol Pharm. 2015; 12(11):4026-37. DOI: 10.1021/acs.molpharmaceut.5b00463. View

12.

Mao Q, Deeley R, Cole S . Functional reconstitution of substrate transport by purified multidrug resistance protein MRP1 (ABCC1) in phospholipid vesicles. J Biol Chem. 2000; 275(44):34166-72. DOI: 10.1074/jbc.M004584200. View

13.

Bruggemann E, Germann U, Gottesman M, Pastan I . Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine. J Biol Chem. 1989; 264(26):15483-8. View

14.

Seelig A . Unraveling membrane-mediated substrate-transporter interactions. Biophys J. 2006; 90(11):3825-6. PMC: 1459502. DOI: 10.1529/biophysj.106.082008. View

15.

Fischer H, Gottschlich R, Seelig A . Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol. 1998; 165(3):201-11. DOI: 10.1007/s002329900434. View

16.

Longley D, Johnston P . Molecular mechanisms of drug resistance. J Pathol. 2005; 205(2):275-92. DOI: 10.1002/path.1706. View

17.

Gatlik-Landwojtowicz E, Aanismaa P, Seelig A . Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry. 2006; 45(9):3020-32. DOI: 10.1021/bi051380+. View

18.

Senior A, Urbatsch I . The catalytic cycle of P-glycoprotein. FEBS Lett. 1995; 377(3):285-9. DOI: 10.1016/0014-5793(95)01345-8. View

19.

Gottesman M, Pastan I, Ambudkar S . P-glycoprotein and multidrug resistance. Curr Opin Genet Dev. 1996; 6(5):610-7. DOI: 10.1016/s0959-437x(96)80091-8. View

20.

Katzenellenbogen M, Mizrahi L, Pappo O, Klopstock N, Olam D, Jacob-Hirsch J . Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Mol Cancer Res. 2007; 5(11):1159-70. DOI: 10.1158/1541-7786.MCR-07-0172. View